167 related articles for article (PubMed ID: 28002201)
1. TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol.
Archer DF; Constantine GD; Simon JA; Kushner H; Mayer P; Bernick B; Graham S; Mirkin S;
Menopause; 2017 May; 24(5):510-516. PubMed ID: 28002201
[TBL] [Abstract][Full Text] [Related]
2. A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.
Simon JA; Archer DF; Constantine GD; Pickar JH; Amadio JM; Bernick B; Graham S; Mirkin S
Maturitas; 2017 May; 99():51-58. PubMed ID: 28364869
[TBL] [Abstract][Full Text] [Related]
3. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women.
Constantine GD; Bouchard C; Pickar JH; Archer DF; Graham S; Bernick B; Mirkin S
J Womens Health (Larchmt); 2017 Jun; 26(6):616-623. PubMed ID: 28355090
[TBL] [Abstract][Full Text] [Related]
4. TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women.
Simon JA; Kagan R; Archer DF; Constantine GD; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Aug; 22(4):412-418. PubMed ID: 30862193
[No Abstract] [Full Text] [Related]
5. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
Kingsberg SA; Derogatis L; Simon JA; Constantine GD; Graham S; Bernick B; Gasper G; Mirkin S
J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
[TBL] [Abstract][Full Text] [Related]
6. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.
Constantine GD; Simon JA; Pickar JH; Archer DF; Kushner H; Bernick B; Gasper G; Graham S; Mirkin S;
Menopause; 2017 Apr; 24(4):409-416. PubMed ID: 27922936
[TBL] [Abstract][Full Text] [Related]
7. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
Simon JA; Archer DF; Kagan R; Bernick B; Graham S; Constantine GD; Mirkin S
Menopause; 2017 Sep; 24(9):1003-1010. PubMed ID: 28419068
[TBL] [Abstract][Full Text] [Related]
8. Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR.
Kingsberg SA; Kroll R; Goldstein I; Kushner H; Bernick B; Graham S; Mirkin S; Constantine GD
Menopause; 2017 Aug; 24(8):894-899. PubMed ID: 28195995
[TBL] [Abstract][Full Text] [Related]
9. Physical characteristics and properties of estradiol softgel vaginal inserts.
Simon JA; Pickar JH; Shadiack AM; Warrier B; Graham S; Bernick B; Mirkin S
Menopause; 2020 Feb; 27(2):150-155. PubMed ID: 31663981
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule.
Pickar JH; Amadio JM; Bernick BA; Mirkin S
Climacteric; 2016 Apr; 19(2):181-7. PubMed ID: 26857443
[TBL] [Abstract][Full Text] [Related]
11. Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data.
Constantine GD; Simon JA; Pickar JH; Archer DF; Bernick B; Graham S; Mirkin S
Curr Med Res Opin; 2018 Dec; 34(12):2131-2136. PubMed ID: 30238814
[TBL] [Abstract][Full Text] [Related]
12. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
Liu JH; Bernick B; Mirkin S
Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
[TBL] [Abstract][Full Text] [Related]
13. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
14. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
Constantine G; Millheiser LS; Kaunitz AM; Parish SJ; Graham S; Bernick B; Mirkin S
Menopause; 2019 Nov; 26(11):1259-1264. PubMed ID: 31688572
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
[TBL] [Abstract][Full Text] [Related]
16. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
Kroll R; Archer DF; Lin Y; Sniukiene V; Liu JH
Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
[TBL] [Abstract][Full Text] [Related]
17. Systemic estradiol levels with low-dose vaginal estrogens.
Santen RJ; Mirkin S; Bernick B; Constantine GD
Menopause; 2020 Mar; 27(3):361-370. PubMed ID: 31794498
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert.
Mirkin S; Simon JA; Liu JH; Archer DF; Castro PD; Graham S; Bernick B; Komm B
Menopause; 2021 May; 28(9):998-1003. PubMed ID: 34054104
[TBL] [Abstract][Full Text] [Related]
19. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
Portman DJ; Bachmann GA; Simon JA;
Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
[TBL] [Abstract][Full Text] [Related]
20. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets.
Eugster-Hausmann M; Waitzinger J; Lehnick D
Climacteric; 2010 Jun; 13(3):219-27. PubMed ID: 20423242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
